Forward-Looking Statements

Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the risks and uncertainties related to the development, manufacturing and distribution of Veklury as a treatment for COVID-19, including the uncertainty of the amount and timing of future Veklury revenues and the risk that Gilead may be unable to recoup the expenses incurred to date and future expenses related to the development and production of Veklury and Gilead may be unable to effectively manage the global supply and distribution of Veklury; Gilead’s ability to achieve its anticipated full year 2020 financial results, including as a result of potential adverse revenue impacts from COVID-19, increases in R&D expenses and potential revenues from Veklury; Gilead’s ability to make progress on and achieve its 2021 strategic business development and capital allocation goals; Gilead’s ability to make progress on any of its long-term ambitions laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its antiviral and other programs; Gilead’s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements; the ability of the parties to complete the MYR GmbH acquisition in a timely manner or at all; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timeframes; the possibility of unfavorable results from ongoing and additional clinical trials; the risk that safety and efficacy data from clinical studies may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to submit new drug applications for new product candidates in the currently anticipated timelines; Gilead’s ability to receive regulatory approvals in a timely manner or at all, and the risk that any such approval may be subject to significant limitations on use; Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead’s products; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products; the risk that efforts to control prescription drug prices could have a material adverse effect on Gilead’s business; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; and other risks identified from time to time in Gilead’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”). In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. These forward-looking statements should also be considered in light of various important factors, including, but not limited to, the following: completion of Gilead’s final closing procedures, final adjustments and other developments that may arise in the course of audit procedures. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Information about these and other risks, uncertainties and factors can be found in Gilead’s periodic reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

This presentation includes U.S. GAAP and non-GAAP financial measures, and a reconciliation between these two measures is available on Gilead’s Investors page at investors.gilead.com. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under U.S. GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry.

Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCovy®, DESCovy FOR PREP®, EMTRIVA®, EPLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPSERA®, JYSELECA®, LETAIRIS®, ODEFSEY®, RANEXA®, SOVALDI®, STRIBILD®, TECARTUS™, TRODELYV®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VELKURY®, VEMULIDY®, VIREAD®, VOSEVI®, YESCARTA® and ZYDELIG®.
Maintaining the highest bar for innovation, combining entrepreneurial biotech spirit with global scale and disciplined focus

Building on our legacy to create new possibilities...

To meet significant patient need in virology, oncology, and inflammation

Transformative Therapies

Employer & Partner of Choice

Shareholder Value
2020: Building for Growth

2020 Strategy Execution Highlights

- Completed significant BD activity to enhance commercial portfolio and clinical pipeline
- Increased pipeline size by 50% overall with notable opt-in opportunities
- Re-prioritized programs and created new governance for the portfolio
- Five new product approvals, including COVID-19 treatment, Veklury
- Recruited key talent (research, clinical development, data science, commercial strategy) with significant build in oncology

2020 Select Milestones

Product Approvals:
- TRODELVY™ FDA
- TECARTUS™ FDA
- HEPCLUDEX EMA
- JYSELECA EMA
- Veklury® FDA

1 Measured by asset-indication projects, net change today vs. JPM 2020. 2. Includes Hepcludex. Agreement to acquire Myr has been announced but not yet closed. Closing of transaction subject to antitrust clearance and other conditions
## Full Year 2020 Guidance

<table>
<thead>
<tr>
<th></th>
<th>October 28, 2020</th>
<th>Updated January 11, 2021</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product Sales</strong></td>
<td>$23,000 - $23,500</td>
<td>$24,300 - $24,350</td>
<td>• Reflects strong performance in-line with prior expectations</td>
</tr>
<tr>
<td><strong>Product Sales excluding Veklury</strong></td>
<td>$21,500 - $21,525</td>
<td></td>
<td>• Reflects increased hospitalization rates and utilization during the most recent COVID surge</td>
</tr>
<tr>
<td><strong>Veklury</strong></td>
<td></td>
<td>$2,800 - $2,825</td>
<td></td>
</tr>
</tbody>
</table>
Role of Veklury (remdesivir) More Critical Than Ever

US COVID-19 Hospitalizations increased 4x in Q4

Q4 2020 US Hospitalizations\(^1\)

- 27k 33k 36k 41k 46k 55k 69k 81k 85k 94k 101k 104k 105k 111k

Only FDA Approved Antiviral for COVID-19

~1 in 2
Patients hospitalized in the US treated with Veklury\(^2\)

~1M
US Patients treated with Veklury\(^2\)

40+
Interventional or observational studies\(^3\)

1. Source: Johns Hopkins University COVID-19 Tracker, COVID Tracking Project, IntegriChain 852 and 867 and HHS admissions; 2. Patients treated and utilization estimates based on volume donated and shipped for distribution within the US, assumed average treatment course of 6.25 vials/patient; 3. Interventional or observational studies registered on clinicaltrials.gov either completed, underway or planned evaluating the use of remdesivir alone; as background therapy; or in combination with other agents in patients with COVID-19
Clear Path to Near and Long-Term Growth

- **Deliver on Opportunities in New Therapeutic Areas**
- **Continue Leadership in Antivirals**
- **Prioritize and Execute Across Portfolio**

Illustrative Growth (Excluding Veklury)

New Therapeutic Areas
(Oncology + Inflammation)

Existing Antiviral Base
(Excluding Veklury)

Diverse and Sustainable Portfolio

**Excluding Veklury (remdesivir)**
Growth Driven by Internal and External Innovation

**Near- to Mid-term Growth**

- BIKTARVY®
- Vemlidy
- HEPClONEX

**Mid- to Long-term Growth**

- **lenacapavir**
- **magrolimab**
- TRODELVY™
- Cell Therapy
- Internal assets + Opt-ins: ARCUS, PIONYR, TIZONA
- Internal assets + Galapagos Opt-in Opportunities

---

**Illustrative Growth**

- **GILEAD**

**2021**

- **Antivirals** (Excluding Veklury)

**2030+**

- **Inflammation**
- **Oncology**

1. Excluding Veklury (remdesivir)
Clear Path to Near and Long-Term Growth

Excluding Veklury (remdesivir)

Deliver on Opportunities in New Therapeutic Areas

Continue Leadership in Antivirals

Prioritize and Execute Across Portfolio

Illustrative Growth (Excluding Veklury)

Diverse and Sustainable Portfolio

New Therapeutic Areas (Oncology + Inflammation)

Existing Antiviral Base (Excluding Veklury)
Oncology Now an Important New Pillar of Growth

Key Oncology Portfolio Features

- Multiple new, high-quality therapies across all stages of development and with diverse MOAs
- Approved transformational medicines provide benefit in hematology and solid tumors
- Enhanced oncology expertise through acquisitions supplement Gilead’s capability and improve ability to execute for growth

<table>
<thead>
<tr>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trodelvy ( ^{3} ) mTNBC, mUC, OV (- PARPi)</td>
<td>Trodelvy ( ^{3} ) mTNBC, (incl. NSCLC)</td>
<td>Trodelvy ( ^{3} ) mTNBC, HER2-( mBC )</td>
</tr>
<tr>
<td>Magrolimab ( ^{2} ) DLBCL</td>
<td>Magrolimab (c-KIT)</td>
<td>Magrolimab MDS</td>
</tr>
<tr>
<td>PD-L1 NSCLC</td>
<td>PD-L1 NSCLC</td>
<td>Trodelvy 3L+ UC</td>
</tr>
<tr>
<td>Magrolimab Solid Tumors</td>
<td>Magrolimab AML</td>
<td>Trodelvy 3L+ mTNBC (ASCENT)</td>
</tr>
<tr>
<td>CD73/ TGF( ^{3} ) Solid tumors</td>
<td>Zimberelimab (PD-1) NSCLC</td>
<td></td>
</tr>
<tr>
<td>Yescarta 1L DLBCL</td>
<td>Yescarta 1L DLBCL</td>
<td></td>
</tr>
<tr>
<td>Yescarta (+ rituximab) 3L DLBCL</td>
<td>Yescarta 3L+ UC</td>
<td>Yescarta 2L DLBCL</td>
</tr>
</tbody>
</table>

**Additional late stage trials for Trodelvy across multiple tumor types to be planned in 2021**

\( ^{3} \) Ph1b/2 study; 1. In-licensed from Arcus; 2. sBLA filed and priority review granted; 3. Pivotal P2 study; 4. Partnership with Pfizer; 5. Partnership with Humanigen.
Trodelvy™ as a Cornerstone With Immediate Benefits and Long-Term Potential

- is a foundational therapy offering immediate transformational benefits in 3L+ mTNBC
- sBLAs filed with FDA for full approval in 3L mTNBC and accelerated approval in mUC 3L
- EMA MAA filing in 3L+ mTNBC expected Q1’21
- PFS data readout in 2H 2021 for TROPiCS-02 Phase 3 trial in 3L+ HR+/HER2- mBC (OS data in 2023)

ASCENT (Ph3):
Results in 3L+ mTNBC¹

Increased median Overall Survival to 12.1 from 6.7 months (p<0.0001)

Expansion Plans Across Multiple Tumor Types and Lines of Therapy

Broad Applicability
Trodelvy targets Trop-2 which is expressed in multiple cancers suggesting broad applicability

Combination Potential
Opportunity to combine with checkpoint inhibitors, targeted agents, and/or chemotherapy

Monotherapy and combinations being explored across indications and lines of therapy

Later Lines of Therapy
- Triple-negative Breast Cancer
- HR+/HER2-Breast Cancer
- Bladder Cancer
- Lung Cancer
- Other Trop-2+ tumors

Earlier Lines of Therapy

2025 Market Size¹
- $40B+ Breast Cancer Total
- $8B+ Bladder Cancer Total
- $40B+ NSCLC Total

¹ Evaluate Pharma, December 2020
Clear Path to Near and Long-Term Growth

Excluding Veklury (remdesivir)

- Deliver on Opportunities in New Therapeutic Areas
- Continue Leadership in Antivirals
- Prioritize and Execute Across Portfolio

Illustrative Growth (Excluding Veklury)

New Therapeutic Areas (Oncology + Inflammation)

Existing Antiviral Base (Excluding Veklury)

Diverse and Sustainable Portfolio
Pioneering in HIV: Past, Present, and Future

## Once-a-Day Oral

### Legacy Single-Tablet Regimens
- **Odefsey**
- **Genvoya**
- **STRIBILD**
- **Truvada®**
- **Complera®**

**First STR** → **ATRILA**

- Launched 2006-2016

## Current Single-Tablet Regimens

- **BIKTARVY®** for treatment
- **Descovy** for prevention

- Launched 2018-2019

## Long-Acting

### Investigational Long-Acting Agent

- **Lenacapavir**
  - 6-month dosing
  - Being studied for treatment and prevention

- **Future Launches**

ATRILA (efavirenz 600 mg / emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg tablets), BIKTARVY (bictegravir 50mg / emtricitabine 200mg / tenofovir alafenamide 25mg tablets), COMPLERA (emtricitabine 200mg / rilpivirine 25mg / tenofovir disoproxil fumarate 300mg tablets), DESCOVY (emtricitabine 200mg / tenofovir alafenamide 25mg tablets), GENVOYA (elvitegravir 150mg / cobicistat 150mg / emtricitabine 200mg / tenofovir alafenamide 25mg tablets), ODEFSEY (emtricitabine 200mg / rilpivirine 25mg / tenofovir alafenamide 25mg tablets), STRIBILD (elvitegravir 150mg / cobicistat 150mg / emtricitabine 200mg / tenofovir disoproxil fumarate 300mg, TRUVADA (emtricitabine 200mg / tenofovir disoproxil fumarate 300 mg tablets).
Confident in Biktarvy Near- and Mid-Term Growth

BIKTARVY® is a standard of care once-a-day oral option: safe, efficacious, & convenient

- **#1** Prescribed Regimen in US and Other Regions¹
- **64%** y/y Revenue Growth Q3’20 vs. Q3’19
- **Consensus Projected Peak Sales² of $>10B**
- **US Market Exclusivity Through 2033**

Lenacapavir Could Be A Long-Acting Game-Changer

Lenacapavir Profile Highlights

- Potential first-in-class HIV capsid inhibitor
- Highly potent investigational agent, dosing as infrequently as every 6 months
- Significantly reduced viral load in proof-of-concept Phase 2/3 hTE\(^1\) trial\(^{Capella}\)
  - Anticipate FDA submission in 2H 2021
- FDA Breakthrough Designation\(^2\)

6-month Dosing Unlocks Significant Potential

- Assuming equal safety, efficacy, and cost, more people prefer 6-month dosing option

Consumer Preference for Prevention Options\(^3\)

<table>
<thead>
<tr>
<th>Dosing Option</th>
<th>Preference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily Oral Therapy</td>
<td>49%</td>
</tr>
<tr>
<td>Intramuscular Injection Every 2 Months</td>
<td>8%</td>
</tr>
<tr>
<td>Sub-cutaneous Injection Every 6 Months</td>
<td>42%</td>
</tr>
</tbody>
</table>

1. hTE = Heavily Treatment Experienced 2. GS-6207 received breakthrough therapy designation from FDA as a potential therapy for heavily treatment-experienced (hTE) people living with multi-drug resistant HIV. 3. Q2 2020 Gilead HIV prevention market research of at-risk individuals conducted across US (n=120), EU4 (n=120), UK (n=30), Canada (n=30) and Australia (n=30)
Accelerating Development of Lenacapavir in HIV Long-Acting Treatment and Prevention

**Treatment**

- 6-month data in treatment naïve population expected 2H 2021
- Exploring internal and external partners for optimal combination regimens
  - Flexible dosing profile (oral and parenteral) supports possibility of *multiple long-acting duration options*
  - Potential combination regimen(s) expected to enter clinic in next 12-18 months

**Prevention**

- **Monotherapy** may be sufficient
- 6-month dosing could meet significant unmet need, materially increasing market size
- Studies to initiate in 2021:
  - Cisgender men, transgender women, transgender men, and gender non-binary people who have sex with men 1H 2021
  - Adolescent girls and young women 2H 2021

1. hTE = Heavily Treatment Experienced
Progress in Viral Hepatitis Further Strengthens Core Antiviral Business

Expected HBV Sales of $1B+ by 2022\(^1\)

- **2019**: $743M
- **2022**: $1B+

**Continuing to lead in HBV Cure**: Ph2 combination studies to initiate this year

**Novel HDV Therapy, Synergies with HBV**

- Hepcludex\(^+\) TDF
- TDF

\(^{1}\) Potential to achieve $1 billion+ franchise by 2022 through U.S. and China Vemlidy growth. 2. From agreement to acquire Myr. Transaction has been announced but not yet closed. Closing of transaction subject to antitrust clearance and other conditions. 3. Undetectable HDV RNA or >2log decline. 4. ALT normalization.
Clear Path to Near and Long-Term Growth

Excluding Veklury (remdesivir)

Deliver on Opportunities in New Therapeutic Areas

Continue Leadership in Antivirals

Prioritize and Execute Across Portfolio

Illustrative Growth (Excluding Veklury)

New Therapeutic Areas (Oncology + Inflammation)

Existing Antiviral Base (Excluding Veklury)

Diverse and Sustainable Portfolio
**Sustainable, More Diverse Portfolio**

**Key Features of Transformed Portfolio**

- Growth drivers have high probability of success from on-market status (e.g. Trodelvy) or compelling data (e.g. lenacapavir)

- Smart deal structures de-risk investments, providing opt-in rights after proof-of-concept data is in hand

**Prioritization to Drive Value**

- >50% expansion of pipeline\(^1\) with higher value programs provides opportunity to **re-prioritize** programs of less value

Select **re-prioritization** examples:

- **Filgotinib**: stopped clinical trials in psoriatic arthritis, ankylosing spondylitis, and non-infectious uveitis
- **NASH**: not pursuing pivotal trial in favor of Phase 2b
- Outlicensing of SYK inhibitor

---

\(^1\) As measured by asset-indication projects, net change from today vs. JPM 2020
Select 2021 Milestones

Lenacapavir capsid inhibitor
Phase 3 initiation for PrEP

Hepcludex¹ (Bulevirtide)
Phase 3 data readout in HDV

Trodelvy (Sacituzumab govitecan-hziy)
MAA filing in 3L mTNBC

Trodelvy (Sacituzumab govitecan-hziy)
Anticipated sBLA full approval in 3L mTNBC

Trodelvy (Sacituzumab govitecan-hziy)
Anticipated sBLA approval in 3L mUC

Magrolimab
Phase 3 initiation in AML

Yesarta (Axi-cel)
Phase 3 data read out in 2L DLBCL

Yesarta (Axi-cel)
Anticipated MAA filing in iNHL

Yesarta (Axi-cel)
Anticipated sBLA approval in iNHL

Tecartus (Brexu-cel)
Anticipated sBLA/MAA submission in adult ALL

Domvanilimab (TIGIT)
Phase 2 interim read out in NSCLC (ARC-7)

Ziritaxestat ATX inhibitor
Phase 3 futility analysis data read out in IPF

COVID-19 Impact: Some clinical trials continue to be impacted by the pandemic, which may result in delays in achieving milestones.

1 From agreement to acquire Myr. Transaction has been announced but not yet closed. Closing of transaction subject to antitrust clearance and other conditions.
2021 Strategic Business Development

2020

- 18 Strategic Partnerships & Acquisitions
  - 12 Gilead Molecules
  - 14+ Opt-in Molecules

2021

- Continued focus on transformative science
- Execute on opportunities from recent BD activity
- Pursue bolt-ons with very high bar, remain opportunistic re: exceptional medicines

1. Excludes divestitures, equity investments and GLPG restructuring; 2. Includes preclinical, excludes target discovery deals
2021 Capital Allocation

Guiding Principles

We will:

- Continue to invest in our business and R&D pipeline while managing expenses
- Grow our dividend and pay down at least $4B of debt
- Repurchase shares
Clear path to growth (excluding Veklury) through strategic transformation of our portfolio

Important new pillar of growth in oncology with Trodelvy as cornerstone

Strong antiviral foundation with continued leadership in HIV

Sustainable growth will be driven by continued internal and external innovation
  - Financial strength and flexibility to continue strategic BD investments
Overview of Clinical Pipeline Today

53 Clinical stage programs¹ through BD since Jan '19

18 NDA/BLA/MAA filings, P3 and Registrational P2 trials

15 Clinical stage NMEs via in-licensing, and acquisitions accounting for 23 programs

7 Breakthrough Therapy Designations

¹ Including in-licensed or acquired programs currently between phase 1 and NDA/BLA/MAA approval.
## Viral Disease Pipeline

### Phase 1
- **Pre-Clinical**
- **Phase 1**
- **Phase 2**
- **Phase 3**
- **Filed**

### EV
- **Veklury® (remdesivir for injection)**: Outpatient COVID-19
- **Remdesivir inhaled form (GS-5794)**: Outpatient COVID-19
- **Remdesivir sub cutaneous form (GS-5794)**: COVID-19

### EV – Emerging viruses
- **bNAb combination (GS-5423, GS-2872)**
- **Lefitolimod TLR-9 agonist (GS-1703)**
- **Vesatolimod TLR-7 agonist (GS-9620)**

### HIV
- **Lenacapavir capsid inhibitor (GS-6207)**: HIV LA HTE
- **Lenacapavir capsid inhibitor (GS-6207)**: HIV LA VS
- **bNAb combination (GS-5423, GS-2872)**
- **Lefitolimod TLR-9 agonist (GS-1703)**
- **Vesatolimod TLR-7 agonist (GS-9620)**
- **Elipovimab bNAb (GS-9722)**
- **Effector IgG #2 (GS-9723)**: HIV Cure
- **Unboosted protease inhibitor (GS-1156)**: HIV Treatment
- **Long acting bictegravir (GS-9883)**: HIV LA
- **Long acting oral combination**
- **Lenacapavir capsid inhibitor (GS-6207)**: HIV PrEP
- **Hookipa HIV vaccine**

### HBV & HDV
- **Hepcludex® (bulevirtide)**
- **Hepcludex® (bulevirtide) + PEG-INF**
- **Selgantolimod TLR-8 agonist (GS-9688)**
- **Oral PD-L1 small molecule (GS-4224)**
- **Hookipa HBV vaccine (GS-6779)**

### Updates since Q3’20
- **Expanded indication**

### Notes
- Non-Gilead sponsored trial(s) ongoing.
- From agreement to acquire Myr. Transaction has been announced but not yet closed. Closing of transaction subject to antitrust clearance and other conditions.
- EV – Emerging viruses
- bNAb – Broadly neutralizing antibody
- HTE – Heavily treatment-experienced
- LA – Long Acting
- VS – Virologically suppressed

Pipeline shown above as of end of Q4’20.
## Inflammatory Disease Pipeline

### Inflammatory Disease

<table>
<thead>
<tr>
<th>Name</th>
<th>Condition</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Filed</th>
<th>Updates since Q3’20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filgotinib JAK-1 inhibitor (GS-6034)</td>
<td>Ulcerative colitis</td>
<td>▲</td>
<td></td>
<td></td>
<td></td>
<td>MAA filed</td>
</tr>
<tr>
<td>Filgotinib JAK-1 inhibitor (GS-6034)</td>
<td>Crohn’s Disease</td>
<td></td>
<td>▲</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Filgotinib JAK-1 inhibitor (GS-6034)</td>
<td>Psoriatic arthritis</td>
<td>▲</td>
<td></td>
<td></td>
<td></td>
<td>Removed from pipeline</td>
</tr>
<tr>
<td>Filgotinib JAK-1 inhibitor (GS-6034)</td>
<td>Ankylosing spondylitis</td>
<td>▲</td>
<td></td>
<td></td>
<td></td>
<td>Removed from pipeline</td>
</tr>
<tr>
<td>Filgotinib JAK-1 inhibitor (GS-6034)</td>
<td>Uveitis</td>
<td>▲</td>
<td></td>
<td></td>
<td></td>
<td>Removed from pipeline</td>
</tr>
<tr>
<td>TPL2 inhibitor (GS-4875)</td>
<td>Ulcerative colitis</td>
<td>▲</td>
<td></td>
<td></td>
<td></td>
<td>Removed from pipeline</td>
</tr>
<tr>
<td>TPL2 inhibitor (GS-5290)</td>
<td>Inflammatory Bowel Disease</td>
<td>★</td>
<td></td>
<td></td>
<td></td>
<td>New</td>
</tr>
<tr>
<td>IRAK4 inhibitor (GS-5718)</td>
<td>Inflammatory Bowel Disease</td>
<td></td>
<td>★</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRAK4 inhibitor (GS-5718)</td>
<td>Lupus</td>
<td></td>
<td>★</td>
<td></td>
<td></td>
<td>New</td>
</tr>
<tr>
<td>Tirabrutintib BTK inhibitor (GS-4059)</td>
<td>CSU</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>New</td>
</tr>
<tr>
<td>α4β7 inhibitor (GS-1427)</td>
<td>Inflammatory Bowel Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small molecule inhibitor (neutrophil target)</td>
<td>Inflammatory Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small molecule inhibitor (innate immunity target)</td>
<td>Inflammatory Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cilofexor FXR agonist (GS-9674)</td>
<td>PSC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ziritaxestat ATX inhibitor (GLPG-1690)</td>
<td>IPF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cilofexor / firsocostat combination</td>
<td>NASH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selonsertib ASK1 inhibitor (GS-4997)</td>
<td>DKD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ziritaxestat ATX inhibitor (GLPG-1690)</td>
<td>Systemic Sclerosis</td>
<td>▲</td>
<td></td>
<td></td>
<td></td>
<td>Removed from pipeline</td>
</tr>
</tbody>
</table>

### Fibrotic Disease

<table>
<thead>
<tr>
<th>Name</th>
<th>Disease</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Filed</th>
<th>Updates since Q3’20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilofexor FXR agonist (GS-9674)</td>
<td>PSC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ziritaxestat ATX inhibitor (GLPG-1690)</td>
<td>IPF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cilofexor / firsocostat combination</td>
<td>NASH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selonsertib ASK1 inhibitor (GS-4997)</td>
<td>DKD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ziritaxestat ATX inhibitor (GLPG-1690)</td>
<td>Systemic Sclerosis</td>
<td>▲</td>
<td></td>
<td></td>
<td></td>
<td>Removed from pipeline</td>
</tr>
</tbody>
</table>

### Galapagos

<table>
<thead>
<tr>
<th>Name</th>
<th>Disease</th>
<th>Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Galapagos</td>
<td>Inflammatory and Fibrosis Diseases</td>
<td>8 clinical stage programs</td>
</tr>
<tr>
<td>Galapagos</td>
<td>Inflammatory and Fibrosis Diseases</td>
<td>Multiple pre-clinical stage programs</td>
</tr>
</tbody>
</table>

---

## Oncology Cell Therapy Pipeline

<table>
<thead>
<tr>
<th>Cell Therapy</th>
<th>Pre-Clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Filed</th>
<th>Updates since Q3’20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tecartus™ (Brexu-cel)¹</td>
<td>MCL</td>
<td></td>
<td></td>
<td></td>
<td>MAA and BLA Approved</td>
<td>MAA approved</td>
</tr>
<tr>
<td>Axi-cel</td>
<td>INHL</td>
<td></td>
<td></td>
<td></td>
<td>sBLA Filed</td>
<td></td>
</tr>
<tr>
<td>Yescarta® (Axi-cel)</td>
<td>2L DLBCL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yescarta® (Axi-cel)</td>
<td>1L DLBCL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brexu-cel</td>
<td>Adult ALL</td>
<td></td>
<td></td>
<td></td>
<td>Pivotal</td>
<td></td>
</tr>
<tr>
<td>Brexu-cel</td>
<td>Pediatric ALL</td>
<td></td>
<td></td>
<td></td>
<td>Pivotal</td>
<td></td>
</tr>
<tr>
<td>Yescarta® (Axi-cel)²</td>
<td>3L DLBCL (+rituximab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yescarta® (Axi-cel)³</td>
<td>3L DLBCL (+lenzilumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yescarta® (Axi-cel)⁴</td>
<td>3L DLBCL (+utomilumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KITE-718 (MAGE-A3/A6)⁵</td>
<td>Solid Tumor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KITE-439 (HPV-16 E7)³</td>
<td>Solid Tumor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brexu-cel</td>
<td>CLL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KITE-037 (Allo-HD CD19)⁶</td>
<td>R/R DLBCL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KITE-222 (CLL-1)</td>
<td>AML</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KITE-363 (Dual targeting)</td>
<td>R/R DLBCL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


## Oncology Non-Cell Therapy Pipeline

<table>
<thead>
<tr>
<th>Non-Cell Therapy</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Filed</th>
<th>Updates since Q3’20</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TrodELVA</strong>™ Sacituzumab govitecan-hziy&lt;sup&gt;1&lt;/sup&gt;</td>
<td>mTNBC (3L)</td>
<td></td>
<td></td>
<td>sBLA</td>
<td>sBLA filed for full approval</td>
</tr>
<tr>
<td>Sacituzumab govitecan-hziy (GS-0132)</td>
<td>Urothelial (3L+)</td>
<td></td>
<td></td>
<td>sBLA for AA</td>
<td>sBLA filed for accelerated approval</td>
</tr>
<tr>
<td>Magrolimab anti-CD47 (GS-4721)&lt;sup&gt;2&lt;/sup&gt;</td>
<td>MDS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sacituzumab govitecan-hziy (GS-0132)</td>
<td>HR+/HER2-mBC (3L+)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sacituzumab govitecan-hziy (GS-0132)</td>
<td>Basket (incl. NSCLC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sacituzumab govitecan-hziy (GS-0132) + CPI</td>
<td>mTNBC (1L), mUC, mNSCLC</td>
<td></td>
<td>Phase 1b/2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magrolimab anti-CD47 (GS-4721)</td>
<td>AML</td>
<td></td>
<td>Phase 1b/2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zimberelimab PD1 (GS-0122)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>NSCLC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magrolimab anti-CD47 (GS-4721)</td>
<td>DLBCL</td>
<td></td>
<td>Phase 1b/2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sacituzumab govitecan-hziy (GS-0132) + PARPi</td>
<td>mTNBC, mUC, Ovarian</td>
<td></td>
<td>Phase 1b/2</td>
<td></td>
<td>P1 → P1b/2</td>
</tr>
<tr>
<td>Oral PD-L1 small molecule inhibitor (GS-4224)</td>
<td>NSCLC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-CD73/TGFβ Trap (GS-1423)</td>
<td>ONC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magrolimab anti-CD47 (GS-4721)</td>
<td>Solid Tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flt3R agonist (GS-3583)</td>
<td>ONC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-c-KIT (GS-0174)</td>
<td>TCR</td>
<td></td>
<td>Phase 1a</td>
<td></td>
<td>PC → P1</td>
</tr>
<tr>
<td>Anti-SIRP-a (GS-0189)</td>
<td>ONC</td>
<td></td>
<td>Phase 1a</td>
<td></td>
<td>PC → P1</td>
</tr>
<tr>
<td>MCL1 inhibitor (GS-9716)</td>
<td>ONC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TME target</td>
<td>ONC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T cell activator</td>
<td>ONC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCR8 (GS-1811)</td>
<td>Solid Tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Options</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arcus</td>
<td>ONC</td>
<td></td>
<td>3 clinical stage programs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agenus</td>
<td>Solid Tumors</td>
<td></td>
<td>2 clinical stage programs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tizona</td>
<td>Advanced Cancers</td>
<td></td>
<td>1 clinical stage program</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pionyr</td>
<td>Solid Tumors</td>
<td></td>
<td>2 clinical stage programs</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

<sup>1</sup> Accelerated FDA approval granted.  
<sup>2</sup> Breakthrough and PRIME designation.  
<sup>3</sup> Non-Gilead sponsored trial(s) ongoing.  
Pipeline shown above as of end of Q4’20.